newsfilter
← Latest News
Business Wire·

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Marks major milestone with completion of enrollment in pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T; topline results expected in first quarter of 2026 Closed financing